1-12 of 12
Alshad S. Lalani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Michele L. LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bedard, Funda Meric-Bernstam, Rinaa S. Punglia, Deborah Schrag, Eva M. Lepisto, Fabrice Andre, Lillian Smyth, Semih Dogan, Celeste Yu, Chetna Wathoo, Mia Levy, Lisa D. Eli, Feng Xu, Grace Mann, Alshad S. Lalani, Fei Ye, Christine M. Micheel, Monica Arnedos
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2118–2130.
https://doi.org/10.1158/1078-0432.CCR-21-0885
Published: 13 May 2022
View article titled, Natural History and Characteristics of <em>ERBB2</em>-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Open the PDF for Natural History and Characteristics of <em>ERBB2</em>-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE in another window
Includes: Supplementary data
Journal Articles

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy J. Pluard, Julie R. Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M. Jones, Nancy U. Lin, Eric P. Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Leslie Bucheit, Richard Bryce, Alshad S. Lalani, Lisa A. Carey, Matthew P. Goetz, Feng Gao, Gretchen Kimmick, Mark D. Pegram, Matthew J. Ellis, Ron Bose
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1258–1267.
https://doi.org/10.1158/1078-0432.CCR-21-3418
Published: 01 April 2022
View article titled, The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Open the PDF for The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, Adam M. Brufksy, Simon H. Waters, Sara A. Hurvitz, Beverly Moy, Sung-Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald J. Wallweber, Judith Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5818–5827.
https://doi.org/10.1158/1078-0432.CCR-21-1584
Published: 01 November 2021
View article titled, Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Open the PDF for Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer in another window
Journal Articles

Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer

Ming Zhao, Stephen Scott, Kurt W. Evans, Erkan Yuca, Turcin Saridogan, Xiaofeng Zheng, Heping Wang, Anil Korkut, Christian X. Cruz Pico, Mehmet Demirhan, Bryce Kirby, Scott Kopetz, Irmina Diala, Alshad S. Lalani, Sarina Piha-Paul, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1681–1694.
https://doi.org/10.1158/1078-0432.CCR-20-3017
Published: 15 March 2021
View article titled, Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
Open the PDF for Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer in another window
Journal Articles

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

Elena Ivanova, Mari Kuraguchi, Man Xu, Andrew J. Portell, Luke Taus, Irmina Diala, Alshad S. Lalani, Jihyun Choi, Emily S. Chambers, Shuai Li, Shengwu Liu, Ting Chen, Thanh U. Barbie, Geoffrey R. Oxnard, Jacob J. Haworth, Kwok-Kin Wong, Suzanne E. Dahlberg, Amir A. Aref, David A. Barbie, Magda Bahcall, Cloud P. Paweletz, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2393–2403.
https://doi.org/10.1158/1078-0432.CCR-19-1844
Published: 15 May 2020
View article titled, Use of <em>Ex</em> <em>Vivo</em> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <em>HER2</em> Mutant Non–Small Cell Lung Cancer
Open the PDF for Use of <em>Ex</em> <em>Vivo</em> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <em>HER2</em> Mutant Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

Dhivya R. Sudhan, Luis J. Schwarz, Angel Guerrero-Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. González Ericsson, Melinda Sanders, Justin M. Balko, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 771–783.
https://doi.org/10.1158/1078-0432.CCR-18-1131
Published: 15 January 2019
View article titled, Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial
Open the PDF for Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial in another window
Includes: Supplementary data
Journal Articles

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Sarah Croessmann, Luigi Formisano, Lisa N. Kinch, Paula I. Gonzalez-Ericsson, Dhivya R. Sudhan, Rebecca J. Nagy, Aju Mathew, Eric H. Bernicker, Massimo Cristofanilli, Jie He, Richard E. Cutler, Jr, Alshad S. Lalani, Vincent A. Miller, Richard B. Lanman, Nick V. Grishin, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 277–289.
https://doi.org/10.1158/1078-0432.CCR-18-1544
Published: 03 January 2019
View article titled, Combined Blockade of Activating <em>ERBB2</em> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Open the PDF for Combined Blockade of Activating <em>ERBB2</em> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Cynthia X. Ma, Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric Winer, Michael Naughton, Matthew P. Goetz, Christy Russell, Debu Tripathy, Melody Cobleigh, Andres Forero, Timothy J. Pluard, Carey Anders, Polly Ann Niravath, Shana Thomas, Jill Anderson, Caroline Bumb, Kimberly C. Banks, Richard B. Lanman, Richard Bryce, Alshad S. Lalani, John Pfeifer, Daniel F. Hayes, Mark Pegram, Kimberly Blackwell, Philippe L. Bedard, Hussam Al-Kateb, Matthew J.C. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5687–5695.
https://doi.org/10.1158/1078-0432.CCR-17-0900
Published: 01 October 2017
View article titled, Neratinib Efficacy and Circulating Tumor DNA Detection of <em>HER2</em> Mutations in <em>HER2</em> Nonamplified Metastatic Breast Cancer
Open the PDF for Neratinib Efficacy and Circulating Tumor DNA Detection of <em>HER2</em> Mutations in <em>HER2</em> Nonamplified Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies

Kyriakos P. Papadopoulos, Sanjay Goel, Murali Beeram, Alvin Wong, Kavita Desai, Missak Haigentz, María L. Milián, Sridhar Mani, Anthony Tolcher, Alshad S. Lalani, John Sarantopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7110–7115.
https://doi.org/10.1158/1078-0432.CCR-08-0483
Published: 03 November 2008
View article titled, A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies
Open the PDF for A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies in another window
Journal Articles

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

Mark R. Albertella, Paul M. Loadman, Philip H. Jones, Roger M. Phillips, Roy Rampling, Neil Burnet, Chris Alcock, Alan Anthoney, Egils Vjaters, Chris R. Dunk, Peter A. Harris, Alvin Wong, Alshad S. Lalani, Chris J. Twelves
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1096–1104.
https://doi.org/10.1158/1078-0432.CCR-07-4020
Published: 15 February 2008
View article titled, Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study
Open the PDF for Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study in another window
Includes: Supplementary data
Journal Articles

Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

Alshad S. Lalani, Susan E. Alters, Alvin Wong, Mark R. Albertella, Jeffrey L. Cleland, William David Henner
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2216–2225.
https://doi.org/10.1158/1078-0432.CCR-06-2427
Published: 02 April 2007
View article titled, Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer
Open the PDF for Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer in another window
Journal Articles

Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy

Betty Li, Alshad S. Lalani, Thomas C. Harding, Bo Luan, Kathryn Koprivnikar, Guang Huan Tu, Rodney Prell, Melinda J. VanRoey, Andrew D. Simmons, Karin Jooss
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (22): 6808–6816.
https://doi.org/10.1158/1078-0432.CCR-06-1558
Published: 22 November 2006
View article titled, Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy
Open the PDF for Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy in another window